Table 3.
Treatment and Prognosis of Patients Who Relapsed After HSCT.
| No. | Relapse time | Relapse sites | Main treatment | Effect | Outcome |
|---|---|---|---|---|---|
| P1 | 3 m+ | Bone marrow | Treatment abandoning | – | Death |
| P2 | 4 m+ | Bone marrow, testiclesskin | DLI, Treatment abandoning | – | Death |
| P3 | 4 m+ | Myeloid sarcoma | Secondary HSCT | Second relapse of myeloid sarcoma | Death |
| P4 | 5 m+ | Bone marrow, mesentery, submandibular gland | Treatment abandoning | – | Death |
| P5 | 15 m+ | Bone marrow (molecular biology) | Secondary HSCT | Sustained CR, MRD Fluctuation, given DLI again | Survival |
| P6 | 22 m+ | CNS | Secondary HSCT | CNS (–) | Survival |
| P7 | 26 m+ | Bone marrow (molecular biology) | DLI | Sustained CR, MRD Fluctuation | Survival |
| P8 | 35 m+ | Bone marrow | Secondary HSCT | Sustained CR | Survival |
| P9 | 46 m+ | Bone marrow (molecular biology) | Secondary HSCT | Sustained CR, MRD (–) | Survival |
CNS: central nervous system; CR: complete remission; DLI: donor lymphocyte infusion; HSCT: hematopoietic stem cell transplantation; m: month; MRD: minimal residual disease; Relapse time: from the day of stem cell infusion.